| RNA-guided editing of bacterial genomes using CRISPR-Cas systems W Jiang, D Bikard, D Cox, F Zhang, LA Marraffini Nature biotechnology 31 (3), 233-239, 2013 | 2490 | 2013 |
| Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system D Bikard, W Jiang, P Samai, A Hochschild, F Zhang, LA Marraffini Nucleic acids research 41 (15), 7429-7437, 2013 | 1093 | 2013 |
| Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials D Bikard, CW Euler, W Jiang, PM Nussenzweig, GW Goldberg, X Duportet, ... Nature biotechnology 32 (11), 1146-1150, 2014 | 753 | 2014 |
| Cas9 specifies functional viral targets during CRISPR–Cas adaptation R Heler, P Samai, JW Modell, C Weiner, GW Goldberg, D Bikard, ... Nature 519 (7542), 199-202, 2015 | 431 | 2015 |
| CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection D Bikard, A Hatoum-Aslan, D Mucida, LA Marraffini Cell host & microbe 12 (2), 177-186, 2012 | 377 | 2012 |
| PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data JR Garneau, F Depardieu, LC Fortier, D Bikard, M Monot Scientific reports 7 (1), 1-10, 2017 | 311 | 2017 |
| Divergent evolution of duplicate genes leads to genetic incompatibilities within A. thaliana D Bikard, D Patel, C Le Metté, V Giorgi, C Camilleri, MJ Bennett, O Loudet Science 323 (5914), 623-626, 2009 | 294 | 2009 |
| Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting GW Goldberg, W Jiang, D Bikard, LA Marraffini Nature 514 (7524), 633-637, 2014 | 257 | 2014 |
| Conjugative DNA transfer induces the bacterial SOS response and promotes antibiotic resistance development through integron activation Z Baharoglu, D Bikard, D Mazel PLoS genetics 6 (10), e1001165, 2010 | 252 | 2010 |
| Consequences of Cas9 cleavage in the chromosome of Escherichia coli L Cui, D Bikard Nucleic acids research 44 (9), 4243-4251, 2016 | 196 | 2016 |
| Crispr-cas component systems, methods and compositions for sequence manipulation F Zhang, L Cong, DBT Cox, P Hsu, LIN Shuailiang, RAN Fei, RJ Platt, ... US Patent App. 14/105,035, 2014 | 189 | 2014 |
| Folded DNA in action: hairpin formation and biological functions in prokaryotes D Bikard, C Loot, Z Baharoglu, D Mazel Microbiology and Molecular Biology Reviews 74 (4), 570-588, 2010 | 189 | 2010 |
| Crispr-cas component systems, methods and compositions for sequence manipulation F Zhang, DBT Cox, L Marraffini, DO Bikard, W Jiang US Patent App. 14/497,627, 2015 | 171 | 2015 |
| CRISPR-Cas component systems, methods and compositions for sequence manipulation F Zhang, DBT Cox, L Marraffini, DO Bikard, W Jiang, NE Sanjana US Patent 9,822,372, 2017 | 159 | 2017 |
| A CRISPRi screen in E. coli reveals sequence-specific toxicity of dCas9 L Cui, A Vigouroux, F Rousset, H Varet, V Khanna, D Bikard Nature communications 9 (1), 1-10, 2018 | 148 | 2018 |
| Innate and adaptive immunity in bacteria: mechanisms of programmed genetic variation to fight bacteriophages D Bikard, LA Marraffini Current opinion in immunology 24 (1), 15-20, 2012 | 135 | 2012 |
| Adapting to new threats: the generation of memory by CRISPR‐Cas immune systems R Heler, LA Marraffini, D Bikard Molecular microbiology 93 (1), 1-9, 2014 | 117 | 2014 |
| Genome-wide CRISPR-dCas9 screens in E. coli identify essential genes and phage host factors F Rousset, L Cui, E Siouve, C Becavin, F Depardieu, D Bikard PLoS genetics 14 (11), e1007749, 2018 | 115 | 2018 |
| Using CRISPR-Cas systems as antimicrobials D Bikard, R Barrangou Current opinion in Microbiology 37, 155-160, 2017 | 99 | 2017 |
| Crispr-cas component systems, methods and compositions for sequence manipulation F Zhang, DBT Cox, L Marraffini, DO Bikard, W Jiang, NE Sanjana US Patent App. 15/887,377, 2018 | 91 | 2018 |
Luciano MarraffiniThe Rockefeller UniversityVerified email at rockefeller.edu
